KRAS and colorectal carcinoma: These two subcategories, which show different therapeutic perspectives, could be instrumental in providing further insights into the molecular mechanisms of tumorigenesis and identifying new molecular targets to improve the therapeutic strategies of KRAS mutated CRC patients.